FDA approves Lytenava for wet AMD

The FDA approved Lytenava for the treatment of neovascular age-related macular degeneration, according to a press release from Outlook Therapeutics.The approval of Lytenava is marks the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the United States.